Knodel et al., 1987 - Google Patents
Adverse effects of hypolipidaemic drugsKnodel et al., 1987
- Document ID
- 10366333739767932717
- Author
- Knodel L
- Talbert R
- Publication year
- Publication venue
- Medical Toxicology and Adverse Drug Experience
External Links
Snippet
Summary Cholestyramine, colestipol, clofibrate, gemfibrozil, nicotinic acid (niacin), probucol, neomycin, and dextrothyroxine are the most commonly used drugs in the treatment of hyperlipoproteinaemic disorders. While adverse reaction data are available for all of them …
- 239000003814 drug 0 title abstract description 19
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Knodel et al. | Adverse effects of hypolipidaemic drugs | |
| Houston et al. | Drug biotransformation interactions in man VI: acetaminophen and ascorbic acid | |
| US5679716A (en) | Pharmaceutical composition for treating osteoporosis | |
| de Wolff et al. | Clinical pharmacokinetics of methoxsalen and other psoralens | |
| Strong et al. | Pharmacokinetics in man of the N-acetylated metabolite of proeainamide | |
| Jones et al. | P-Hydroxybenzoic acid esters as preservatives III.: the physiological disposition of p-Hydroxybenzoic acid and its esters | |
| Bonsignore et al. | A case of suicide by ingestion of caffeine | |
| Evans et al. | Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of α-lipoic acid | |
| JPS63502437A (en) | Oxygenated cholesterol-containing compositions and their use for the local treatment of diseases | |
| Minodier et al. | Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients | |
| Oliveira-Neto et al. | Mucosal leishmaniasis (" espundia") responsive to low dose of N-methyl glucamine (Glucantime®) in Rio de Janeiro, Brazil | |
| Blumenthal et al. | Plasma nitroglycerin levels after sublingual, oral and topical administration | |
| Graefe-Mody et al. | A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects | |
| Madsen et al. | Acute propoxyphene self‐poisoning in 222 consecutive patients | |
| Bélanger et al. | Effect of sodium polystyrene sulfonate on lithium bioavailability | |
| Leonards et al. | Gastrointestinal blood loss from aspirin and sodium salicylate tablets in man | |
| Uribe et al. | Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers | |
| Zhou et al. | In vitro dissolution and in vivo bioequivalence evaluation of two metformin extended‐release tablets | |
| Vaz-da-Silva et al. | Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions | |
| EVANS et al. | Adrenal hormone therapy in viral hepatitis. III. The effect of ACTH and cortisone in severe and fulminant cases | |
| Liu et al. | Retraction: Pharmacokinetic Interaction of Paeoniflorin and Sinomenine: Pharmacokinetic Parameters and Tissue Distribution Characteristics in Rats and Protein Binding Ability In Vitro | |
| Cressman et al. | Absorption and excretion of tolmetin in man | |
| KR100247441B1 (en) | Transdermal Pharmaceutical Aspirin Composition for Thromboxane Level Inhibition | |
| EP0190851A1 (en) | Improved antiinflammatory composition | |
| US20110262567A1 (en) | Composition for treating gout, containing angelica gigas extract having a xanthine oxidase-inhibiting effect and an inflammation-inducing enzyme-inhibiting effect |